Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast by Munaut, Carine et al.
Published in: Human Reproduction (2008), vol. 23, iss. 6, pp. 1407-1415 
Status: Postprint (Author’s version) 
 
Hypoxia is responsible for soluble vascular endothelial growth factor 
receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous 
trophoblast 
Carine Munaut1, Sophie Lorquet1,2, Christel Pequeux1, Sylvia Blacher1, Sarah Berndt1, Francis Frankenne1 and 
Jean-Michel Foidart1,2
1Laboratory of Tumor and Development Biology, CRCE, CHU, GIGA, University of Liège, Tour de Pathologie (B23), Sart Tilman B-4000, 
Liège, Belgium; 2Department of Obstetrics and Gynecology, Hôpital of la Citadelle, Liège, Belgium 
Abstract 
BACKGROUND: Pre-eclampsia is a pregnancy disorder characterized by a maternal endothelial cell 
dysfunction associated with low levels of circulating placental growth factor (PlGF) and increased levels of total 
vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1), and soluble endoglin, a 
transforming growth factor βl and 3 coreceptor. Here, we tested the hypothesis that these altered levels of 
angiogenic cytokines and of the anti-angiogenic soluble forms of cytokine receptors could be the consequence of 
hypoxia.  
METHODS: Normal human umbilical vein endothelial cells, immortalized first trimester extravillous 
trophoblast cells (HTR8/SVneo) and first trimester placental villi expiants (8-14 weeks) were used for culture 
under normoxia (20% O2) or hypoxia (1% O2). Culture media were collected for the measurement of cytokines 
by enzyme-linked immunosorbent assay. Total RNA was extracted for RT-PCR analysis.  
RESULTS: Under hypoxia, villous trophoblast expressed higher levels of VEGF, VEGFR-1, sVEGFR-1 and 
VEGFR-2 mRNAs (P < 0.001), and secreted more VEGF and sVEGFR-1 proteins (P<0.05). In contrast, P1GΓ 
mRNA and protein were decreased in 1% O2 (P < 0.001), whereas endoglin (Eng) was not modulated. 
Additionally, sVEGFR-1 directly abolished VEGF/PlGF-induced angiogenesis in the rat aortic ring assay.  
CONCLUSIONS: Our results support the hypotheses that, in pre-eclampsia, (i) overproduction of VEGF family 
factors by pre-eclamptic placenta is a consequence of induced hypoxia; (ii) overproduction of sVEGFR-1 by 
hypoxic villous trophoblast accounts for maternal free VEGF depletion; (iii) low circulating level of free P1GΓ 
is not only related to sVEGFR-1 overproduction, but also to hypoxia-induced mRNA down-regulation; (iv) Eng 
is not modulated by hypoxia. 




Pre-eclampsia is a severe disorder unique to human pregnancy that is characterized by onset of proteinuria and 
hypertension after the 20th week of pregnancy. Etiologic factors are still not fully characterized, although 
evidence supports the involvement of genetic, immune, angiogenic and other mechanisms (Roberts and Cooper, 
2001; Lachmeijer et al., 2002; Bdolah et al., 2004, 2005; Chaouat et al., 2005; Maynard et al., 2005; Roberts and 
Gammill, 2005). 
In normal pregnancy, extravillous cytotrophoblast invades the terminal segments of the uterine arteries 
transforming these small muscular arterioles to large capacitance vessels of low resistance (Zhou et al., 1993, 
1997). This allows increased blood flow (i.e. oxygen, nutrients) to the fetus. Remodeling of the spiral arteries 
probably begins in the late first trimester and is completed by 18-20 weeks of gestation, although the exact 
gestational age at which trophoblast invasion of these arteries ceases is unclear. By comparison, in preeclampsia 
the cytotrophoblast infiltrates the decidual portion of the spiral arteries, but fails to penetrate the myometrial 
portion (Meekins et al., 1994; Naicker et al., 2003; Guzin et al., 2005). Thus, the large, tortuous vascular 
channels created by replacement of the musculoelastic wall with fibrinoid material do not develop. Instead, the 
vessels remain narrow leading to hypoperfusion. This is supposed to impact on the local oxygen pressure leading 
to placental ischemia/hypoxia, and ultimately to functional anomalies of the maternal vascular endothelium 
(Granger et al, 2002; Challier and Uzan, 2003). 
We and others have recently presented evidence that excess secretion of soluble vascular endothelial growth 
factor receptor-1 (sVEGFR-1 also referred as sFlt1), a naturally occurring circulating VEGF antagonist, could be 
responsible for the maternal syndrome (Maynard et al., 2003; Tsatsaris et al., 2003; Levine et al., 2004). 
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Additionally, administration of sVEGFR-1 produces hypertension and proteinuria in pregnant rats (Maynard et 
al., 2003). sVEGFR-1 arises from an alternative splice variant mRNA that lacks the cytoplasmic and 
transmembrane domain but contains the ligand-binding domain of VEGFR-1 (Kendall and Thomas, 1993; 
Kendall et al., 1996). Thus, sVEGFR-1, by forming a complex with VEGF or placental growth factor (PlGF), 
may antagonize the biological activity of these cytokines (Kendall and Thomas, 1993; Autiero et al., 2003a,b). 
Recently, Venkatesha et al. (2006) showed that circulating levels of soluble endoglin (sEng), a coreceptor for 
transforming growth factor β1 and 3 (TGFβ1 and 3), are elevated in women with pre-eclampsia. sEng may 
impair the binding of TGFβ1 and 3 to endothelial receptors, decreasing endothelial nitric oxide synthase-
activated vasodilatation. sEng decreased angio-genesis in vitro, but its overexpression in pregnant rats had only 
minimal effects. However, in pregnant rats the simultaneous introduction of adenoviruses encoding both 
sVEGFR-1 and sEng induced severe hypertension, heavy proteinuria, elevated liver-enzyme levels, creating a 
powerful model that simulates most of the manifestations of pre-eclampsia in humans (Venkatesha et al., 2006). 
Cross-sectional studies suggest that changes in maternal serum levels of sVEGFR-1 and sEng antedate the onset 
of clinical symptoms by 5-8 weeks in healthy, nulliparous women and may be useful for screening or early 
diagnosis of pre-eclampsia (Levine et al., 2004; McKeeman et al., 2004; Levine et al., 2006b; Wathen et al., 
2006). More recently, a pilot study, performed to evaluate the clinical utility of sVEGFR-1 and sEng in the 
differential diagnosis of hypertension in late pregnancy, proved that both cytokines could be useful in 
differentiating pre-eclampsia from other hypertensive diseases of pregnancy (Salahuddin et al., 2007). 
Even though increased soluble factors released in maternal circulation could be the answer to an ischemic 
placenta, mechanisms of action and the source of these factors are not yet fully understood. 
Our study was undertaken to test the hypothesis that placental hypoxia is one of the trigger event leading to the 
massive placental secretion of these soluble angiogenic cytokines and anti-angiogenic receptors. 
MATERIALS AND METHODS 
Cell culture and hypoxia treatment 
Normal human umbilical vein endothelial cells (HUVEC) were isolated by umbilical vein treatment with 0.1% 
collagenase (from Clostridium histolyticum; Sigma, St Louis, MO, USA) as described previously (Jaffe et al., 
1973). HUVEC cells were cultured on gelatin-coated dishes in MCDB 131 (Gibco-BRL, Grand Island, NY, 
USA) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gibco-BRL), 2 mM glutamine (Gibco-
BRL), 5 µg/ml endothelial cell growth factor (BD Biosciences, Bedford, USA), 50 µg/ml heparin (Sigma), 25 
mM HEPES and 100 IU/ml penicillin-streptomycin (Gibco-BRL). 
Immortalized human first trimester extravillous trophoblast cells (HTR8/SVneo), kindly provided by CH 
Graham, Kingston, Ontario, Canada, were routinely grown in RPMI 1640 (Gibco-BRL) supplemented with 10% 
FCS (Gibco-BRL), 2 mM glutamine and 100 IU/ml penicillin-streptomycin. Phenotypic characterization has 
shown that these cells express some markers of extravillous trophoblast cells including cytokeratins, urokinase-
type plasminogen activator receptor (uPAR), matrix metalloproteinase-2 and -9 (MMP-2 and -9). As previously 
described the extravillous trophoblast cells retain the ability to express HLA-G when cultivated on Matrigel 
(Kilburn et al, 2000). 
Between 18 and 24 h before undergoing hypoxia, cells were plated at a density of 1.25 × 105 cells per T-flask 
(12.5 cm2). The medium was changed 1 h before hypoxic or normoxic treatment to ensure an adequate amount of 
nutrient and growth factor. Hypoxic treatment was carried out in an incubator supplied with 1% O2, 5% CO2 and 
94% N2. Normoxic experiments were performed under 20% O2, 5% CO2 and 75% N2. Oxygen concentration was 
monitored using an oxygen electrode (OS1000; Oxygen Sensors, Inc, Frazer, PA). 
Human trophobMst villous expiant culture 
Samples of human placental villi (n = 30) were obtained from first trimester (8-14 weeks) termination of 
pregnancies with agreement of our local medical ethics committee. Informed consent was obtained from the 
patients. Placental tissue was placed in ice-cold phosphatebuffered saline (PBS) and processed within 2 h of 
collection. One part of each tissue sample was fixed in 4% formalin and embedded in paraffin for histological 
analysis, while the other part was used for expiant culture. The tissue was washed in sterile PBS and aseptically 
dissected. Small fragments of placental villi (five pieces of 1-2 mm3) were teased apart and placed on a 
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transparent Biopore membrane of 12-mm diameter Millicell-CM culture dish inserts with a pore size of 0.4 µm 
(Millipore Corp., Bedford, MA). Expiants were cultured in Dulbecco's modified Eagle's medium-Ham's F-12 
(DMEM/F12; Gibco-BRL) supplemented with 100 IU/ml penicillin-streptomycin. Hypoxic treatment was 
carried out in an incubator supplied with 1% O2, 5% CO2 and 94% N2. Normoxic experiments were performed 
under 20% O2, 5% CO2 and 75% N2. Culture media were collected for measurement of VEGF, PlGF, sEng and 
sVEGFR-1. Part of the villous expiant culture was fixed in 4% formalin and the other part was snap frozen in 
liquid N2 and placed at -80°C for RNA extraction. 
Immunoassays for VEGF, sVEGFR-1, PlGF and sEng 
Levels of VEGF, PlGF, sVEGFR-1 and sEng were measured in conditioned medium by sandwich enzyme 
immunoassay technique (R&D Systems® Europe Ltd, Abington, UK for VEGF, PIGF and Eng, or Bender 
MedSytems®, Vienna, Austria for sVEGFR-1). All samples were measured in duplicate. Sensitivity of assays is 
5 pg/ml for VEGF and sEng, 0.1 ng/ml for s VEGFR-1 and 7 pg/ml for PlGF. 
RT-PCR analysis 
Total RNA was extracted with Rneasy Mini Kit (QIAGEN GmbH, Hilden, Germany) according to the 
manufacturer's protocol. Total RNA (1 µg) was reverse transcribed with a Superscript II reverse transcriptase 
(Invitrogen) and random hexamers as primer. 
Real-time quantitative RT-PCR analyses for VEGF, VEGFR-1 sVEGFR-1, VEGFR-2 (KDR/Flk-1), Eng and 
PlGF mRNAs and 18S rRNA were performed using the ABI PRISM 7700 Sequence Detection System 
instrument and software (PE Applied Biosystems Inc., Foster City, CA) as previously described (Tsatsaris et al. 
2003). The sequences of the PCR primer pairs and fluorogenic probes that were used for each gene are shown in 
Table I. 
Table I: Sequence of primers and TaqMan probes used for RT-PCR studies 
Gene and Accession 
no 
Position Sequence Size PCR 
product 
VEGF-FP 748F 5'-TCTACCTCCACCATGCCAAGT-3' 104 bp 
VEGF-RP 851R 5'-GCTGCGCTGATAGACATCCA-3'  
VEGF Probe 797 5'-CCACTTCGTGATGATTCTGCCCTCCT-3'  
NM 003376    
VEGFR1-FP 2438F 5'-TCCCTTATGATGCCAGCAAGT-3' 79 bp 
VEGFR1-RP 2516R 5'-CCAAAAGCCCCTCTTCCAA-3'  
VEGFR1 Probe 2469 5'-CCGGGAGAGACTTAAACTGGGCAAATCA-3'  
AF063657    
sVEGFR1-FP 2209F 5'-ACAATCAGAGGTGAGCACTGCAA-3' 180 bp 
sVEGFR1-RP 2388R 5'-TCCGAGCCTGAAAGTTAGCAA-3'  
sVEGFRl Probe 2257 5'-TCCAAATTTAAAAGCACAAGGAATGATTGTACCAC-3'  
U01 134    
VEGFR2-FP 791F 5'-CTTCGAAGCATCAGCATAAGAAACT-3' 156 bp 
VEGFR2-RP 946R 5'-TGGTCATCAGCCCACTGGAT-3'  
VEGFR2 Probe 820 5'-AACCGAGACCTAAAAACCCAGTCTGGGAGT-3'  
AF063658    
PlGF-FP 668F 5'-CCTACGTGGAGCTGACGTTCT-3' 77 bp 
PlGF-RP 744R 5'-TCCTTTCCGGCTTCATCTTCT-3'  
PlGF Probe 702 5'-CTGCGAATGCCGGCCTCTGC-3'  
X54 936    
Eng-FP 1597F 5'-TCTACCTCCACCATGCCAAGT-3' 70 bp 
Eng-RP 1666R 5'.TTTTTCCGCTGTGGTGATGA-3'  
Eng Probe 1619 5'-TGAGGCGGTGGTCAATATCCTGTCGA-3'  
NM_000118    
F: forward, R: reverse. 
VEGF, vascular endothelial growth factor; VEGFR1, vascular endothelial growth factor receptor-1; sVEGFRl, soluble VEGF receptor-1; 
VEGFR2, VEGF receptor-2; PlGF, placental growth factor; Eng, endoglin. 
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Immunohistochemistry (PlGF, VEGFR-1 and Ki67) 
Placental villi were fixed in 4% formalin for 1 h and then embedded in paraffin. Paraffin sections (4 µm) were 
mounted on aminopropyltriethoxysilane (Tespa)-coated glass slides. 
Sections were dewaxed in xylene and rehydrated. For Ki67 (a marker of cell proliferation) and VEGFR-1 
labeling, antigen retrieval was performed by treatment for 11 min. at 126°C and 1.4 Bar with Target Retrieval 
Solution (DakoCytomation, Glostrup, Denmark, S1699). For PlGF, a pretreatment with citrate buffer 
(DakoCytomation, S2031) was performed. Non-specific antibody binding was blocked by incubation for 20 min 
in a blocking reagent containing 3% H2O2 and for 60 min in 10% serum albumin solution. Then, 50 µg/ml of 
PlGF antibody (mouse monoclonal anti-human PIGF, R&D Systems, MAB264), 5 µg/ml of VEGFR-1 antibody 
(goat anti-human VEGFR-1, R&D Systems, AF312) or monoclonal mouse anti-human Ki67 antigen (1/100, 
clone MIB-1 (DakoCytomation, M7240)) were incubated with the sections for 1 h, at room temperature (PlGF 
and Ki67) or overnight at 4°C (VEGFR-1). Sections were washed in Tris Buffer Saline—0.1% Tween and 
incubated with a secondary antibody, peroxidase conjugated (goat anti-mouse Envision (DakoCytomation, 
K4000)) for KI67 and PlGF, or with a rabbit anti-goat biotin conjugated antibody (DakoCytomation, E466) 
followed by streptavidin/horse-radish peroxidase (DakoCytomation, P397), for VEGFR-1. Staining was detected 
with the diaminobenzi-dine chromogen after 5 min. Nuclei were counterstained by incubation for 2 min. with 
hematoxylin. Sections were mounted, examined and photographed under a Leica—DMLS microscope couple to 
a digital camera (Nikon Coolpix 990). Controls were performed by omitting the primary antibody or by 
incubating the sections with non-specific immunoglobulin G at the same concentration as the primary antibody. 
Aorta ring assay 
Rat aortic rings were cultured in 3D collagen gels as previously described (Blacher et al., 2001; Masson et al., 
2002). Briefly, thoracic aortas were removed from mice sacrificed by cervical dislocation and immediately 
transferred to a culture dish containing ice-cold serum-free minimum essential medium (MEM, Life 
Technologies Ltd, Paisley, Scotland). The peri-aortic fibroadipose tissue was carefully removed. One millimeter 
long aortic rings (~15 per aorta) were sectioned and extensively rinsed in five consecutive washes of MEM. Ring 
shaped expiants of mouse aorta were then embedded in a rat tail interstitial collagen gel (1.5 mg/ml) prepared by 
mixing 7.5 volumes of 2 mg/ml collagen (Collagen R, Serva, Heidelberg, Germany), 1 volume of 10 × MEM, 
1.5 volume of NaHC03 (15.6 mg/ml) and ~0.1 volume of 1 M NaOH to adjust the pH to 7.4. The collagen gels 
containing the aortic rings were polymerized in cylindrical agarose wells and kept in triplicate at 37°C in 60 mm 
diameter Petri dishes (bacteriological polystyrene, Falcon, Becton Dickinson, Lincoln Park, NJ). Each dish 
contained 6 ml of MCDB131 (Life technologies Ltd, Paisley, Scotland) supplemented with 25 mM NaHC03, 
2.5% mouse serum, 1% glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. The cultures were kept at 
37°C in a humidified environment for 9 days and examined with an Olympus microscope at appropriate 
magnification. Effects of recombinant VEGF (Peprotech, Rocky Hill, NJ), PlGF, sVEGFR-1, endoglin and 
TGFβ (R&D Systems, Abingdon, UK) on aortic rings were evaluated after 9 days of incubation. Quantification 
of neoformed micro-vessels number (Vn) was performed by image analysis on a Sun SPARC30 workstation 
with the software Visilog 5.0 from Noesis according to Blacher et al. (2001). 
Statistical analyses 
Mann-Whitney test was used for statistical analysis. Results are shown as mean + SEM. In the aortic ring assay 
Student-Newman-Keuls or Kruskal-Wallis Anova tests were used. A value of P < 0.05 were considered 
statistically significant. 
RESULTS 
Impact of hypoxia on angiogenic cytokines and anti-angiogenic soluble receptors in cell culture 
HUVEC and HTR8/SVneo cells cultured in the presence of 20% O2 contained similar amounts of VEGF mRNA 
levels, as measured by quantitative real-time PCR. After 6 and 24 h of hypoxia (1% O2) VEGF mRNA levels 
were doubled in HUVEC cells (Fig. 1A) and 1.5-fold higher in HTR8/SVneo (Fig. 1B). VEGF secretion 
measured by enzyme-linked immunosorbent assay (ELISA) in medium conditioned by HUVEC cells remained 
undetectable even after 24 h hypoxia, whereas HTR8/SVneo cells doubled their secretion of VEGF in hypoxic 
conditions (Fig. 1C). 
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sVEGFR-1 protein secreted by HUVEC cells was not affected by hypoxia (Fig. 1D). No sVEGFR-1 was 
detected in conditioned medium from HTR8/SVneo cells. Quantitative RT-PCR confirmed that sVEGFR-1 
mRNA was not modulated under hypoxia in HUVEC cells (Fig. 1E) and that HTR8/SVneo cells contained 
minimal amounts of sVEGFR-1 mRNA, ~100 times less than in HUVEC cells (Fig. 1F). In contrast to the 
anticipated rise, sVEGFR-1 mRNA level in HTR8/SVneo cells decreased, but not significantly, upon hypoxic 
treatment. 
Figure 1: Effect of hypoxia on vascular endothelial growth factor (VEGF) and soluble VEGF receptor-1 
(sVEGFR-1) mRNA and secretion. Cells were incubated for 6 or 24 h under normoxia (20% O2) or hypoxia (1% 
O2). mRNA levels of VEGF and sVEGFR-1 in HUVEC cells (A, E) and HTR8/SVneo (B, F) were quantified by 
real-time RT-PCR, normalized by 18S rRNA and expressed as arbitrary units (AU) (mean ± SD), n = 4. Levels of 
VEGF (pg/ml) in HTR8/SVneo (C) and sVEGFR-1 (ng/ml) in HUVEC cells (D) were assessed by enzyme-linked 
immunosorbent assay (ELISA) (mean ± SE), n = 4.*P < 0.05. 
 
Hypoxia in placental villi culture expiants 
Placental villi expiants cultured under hypoxia were used to study the impact of low oxygen on placental 
physiology. 
Tissue integrity in normoxic or hypoxic conditions was assessed by histological analysis after hematoxylin-eosin 
staining and Ki67 labeling. Hypoxia did not alter cell and tissue morphology even after 48 h. Ki67 labeling was 
not significantly different in specimens cultured under 20% O2 or 1 % O2 (Fig. 2A-C'). Immunodetection of 
sVEGFR-1 was particularly evident after culture in 1 % 02, whereas immunodetection of PlGF became faint in 
such specimens (Fig. 2D-I'). 
Hypoxia increased 2- to 4-fold the amount of secreted VEGF after 48 h of culture (14.01 ± 4.10 versus 33.69 ± 
10.91 pg/ml, P = 0.0479) (Fig. 3A). sVEGFR-1 protein was also increased 2-fold in the conditioned medium of 
culture upon hypoxic treatment (7.507 ± 0.519 versus 12.54 ± 2.215 ng/ml, P = 0.0086) (Fig. 3B). In contrast, 
hypoxia caused a 4-fold decrease in secreted PlGF (226.87 ± 39.16 versus 51.44 ± 8.654 pg/ml, P < 0.0001) 
(Fig. 3C). Hypoxia did not modulate sEng level after 48 h of culture (Fig. 3D). Since an imbalance exists 
between the proangiogenic PlGF and the anti-angiogenic sVEGFR-1 in preeclampsia, we calculated 
PlGF/sVEGFR-1 ratio. The ratio was significantly decreased in villous expiants cultured under hypoxia (Fig. 3E, 
39.40 ± 8.393 in normoxia versus 6.794 44 ± 1.507 in hypoxia, P < 0.0001). 
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In cultured expiants, mean levels of VEGF mRNAs significantly increased 5-fold under hypoxia (P < 0.0001) 
(Fig. 4A). In contrast, PlGF mRNA levels decreased 2-fold after 48 h under hypoxia (P = 0.0002) (Fig. 4C). 
Quantification of sVEGFR-1 mRNA levels showed a 5-fold up-regulation under hypoxia (P = 0.0002) (Fig. 4B), 
although the increase of VEGFR-1 mRNA was only 2-fold (P = 0.0004) (Fig. 4E). In our experimental 
conditions, Eng mRNA levels did not show any modulation under hypoxia as compared to normoxia (Fig. 4D). 
VEGFR-2 mRNA exhibited an up-regulation of 10-fold (P = 0.0002) after 48 h of hypoxia (Fig. 4F). 
Collectively these data indicate that oxygen level directly affects the mRNA levels of these cytokines and their 
receptors, but does not modulate endoglin. 
Figure 2: Immunolocalization of Ki67 (A, A', B, B', C and C), VEGFR-1 (D, D', E, E', F and F') and placental 
growth factor (PlGF, G, G', H, H', I and I') in villous expiants before culture (A, A', D,D', G and G'), after 48 h 
under normoxia (20% O2) (B, B', E, E', H and H') or hypoxia (1% O2) (C, C, F, F', I and I'). 
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Figure 3: VEGF, sVEGFR-1, PlGF and soluble endoglin (sEng) secretion in conditioned medium of villous 
expiants after 48 h of culture under normoxia (20% O2) or hypoxia (1% O2). Levels of VEGF (A), sVEGFR-1 
(B), PlGF (C) and sEng (D) were assessed by ELISA and expressed as pg/ml or ng/ml (mean ± SE), n = 30. 
Levels of PlGF and sVEGFR-1 released from placental villous expiants were expressed as ratio (E), n = 30. *P 
< 0.05, **P < 0.01 and ***P < 0.001. 
 
 
sVEGFR-1 and sEng effect on angiogenesis 
In order to further evaluate the consequences of an increased production of sVEGFR-1 or endoglin upon 
endothelial cells and angiogenesis, we next incubated rat aortic rings with angiogenic cytokines VEGF 
(10ng/ml)±PlGF (10ng/ml) mixed with increasing doses of sVEGFR-1 (100 and 250 ng/ ml) or endoglin (100 or 
250 ng/ml). In this model, sVEGFR-1 was able to totally abolish the angiostimulation induced by VEGF+PlGF, 
thus demonstrating the anti-angiogenic effect of excess of sVEGFR-1. Endoglin (100 ng/ml) was not able to 
modulate the neoangiogenesis in this experimental setting whereas a higher dose (250 ng/ml) had some 
additional effect on VEGF/PlGF-driven angiogenesis (Fig. 5A and B). 
Since endoglin has been described as a coreceptor for TGFβ, we performed the same assay with TGFβ present. 
In the presence of TGFβ (15 ng/ml), neoangiogenesis was inhibited and increasing amounts of endoglin was not 
able to reverse this effect (Fig. 5A and C). Endoglin alone did not modulate neoangiogenesis (data not shown) in 
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Figure 4: VEGF, sVEGFR-1, PlGF, Eng, VEGFR-1 and VEGFR-2 mRNA in villous expiants after 48 h of 
culture under normoxia (20% O2) or hypoxia (1% O2). mRNA levels of VEGF (A), sVEGFR-1 (B), PlGF (C), 
Eng (D), VEGFR-1 (E) and VEGFR-2 (F) were quantified by real-time RT-PCR, normalized by 18S rRNA and 




Pre-eclampsia is associated with defect of cytotrophoblasts to invade the spiral arterioles (Zhou etal., 1998). 
Events, that normally take place during the first 20 weeks of pregnancy, which convert the maternal-fetal 
interface from a relatively hypoxic environment to one that is well oxygenated, fail to occur. Consequently, 
villous cytotrophoblast cells remain in a relatively hypoxic environment. In this study, we evaluated if hypoxia 
could be the trigger event at the origin of the abnormal angiogenic protein secretion pattern characterizing pre-
eclampsia. In that view, we compared protein secretion and mRNA expression of these angiogenic proteins in 
first trimester villous expiants cultured under normoxia and hypoxia. Because of the difficulty in obtaining 
tissue, no work was carried out on tissue from pre-eclamptic pregnancies. Low oxygen induces some of the 
classical features of pre-eclampsia such as the up-regulation of sVEGFR-1 and VEGF and an imbalance of PlGF 
to sVEGFR-1 ratio. Interestingly, we demonstrated that the decreased level of circulating PlGF observed in pre-
eclampsia could not only be a consequence of the trapping by sVEGFR-1 overproduced, but could also be due to 
hypoxia-induced PlGF mRNA down-regulation. By comparing mRNA expression of sVEGFR-1 and VEGFR-1, 
we observed that hypoxia increases 2.5-fold more the sVEGFR-1 mRNA transcription. These data strongly 
suggest that hypoxia promotes the alternative splicing of VEGFR-1 pre-mRNA in placenta. However, sEng was 
not shown to be modulated in the same experimental setting. Our data highlight that distinct placental pathogenic 








Published in: Human Reproduction (2008), vol. 23, iss. 6, pp. 1407-1415 
Status: Postprint (Author’s version) 
 
Figure 5: Effect of sVEGR1 and/or endoglin in the aortic ring assay. Rat aortic rings were cultured in a 
collagen gel for 9 days with vehicle (CT), with VEGF+ PlGF (10ng/ml) (V+P), with a combination of sVEGFR-
1 (100 or 250 ng/ml) and VEGF+PlGF (10 ng/ml) (sR1-100 and sR1-250), with a combination of endoglin (100 
or 250 ng/ml) and VEGF+PlGF (10 ng/ml), with transforming growth factor β (TGFβ) (15 ng/ml) or with a 
combination of endoglin (15, 100 or 250 ng/ml) and TGFβ (15 ng/ml). (A) Representative photomicrographs 
(scale 25 × ) of aortic rings after 9 days of incubation (B) and (C) Quantification of microvessel outgrowth by 
computerized image analysis of aortic ring assay. Vn, vessels number; n = 4, mean ± SEM *P < 0.05, **P < 
0.01 and ***P < 0.001. 
 
 
Reduced placental perfusion with attendant placental hypoxia is considered to be an important early feature of 
pregnancies complicated by pre-eclampsia or by intrauterine fetal growth restriction (Khong et al., 1986; 
Brosens et al., 2002). Hypoxia has been shown previously to increase sVEGFR-1 but not VEGF production by 
primary cytotrophoblasts culture (Lash et al., 2002; Nagamatsu et al., 2004). In their primary cytotrophoblasts 
cultures, they also showed a significant increase in the level of total VEGF and a decrease of free PlGF under 
reduced oxygen condition (2,5 and 8% O2). We show here that the extravillous trophoblast cells HTR-8/SVneo 
respond to hypoxia by an increase of VEGF mRNA and protein secretion without any sVEGFR-1 modulation. 
Soluble VEGFR-1 mRNA detected in this extravillous cell lineage was not modulated by hypoxia. Our results 
are in agreement with those of Koklanaris et al. (2006). By microarray analysis, they indeed identified, in 
HTR8/SVneo cells cultured in hypoxic conditions, several hypoxia inducible factor 1 alpha regulated genes, like 
VEGF, tissue inhibitor of metalloproteinases-3 and plasminogen activator inhibitor-1, but sVEGFR-1 was not 
detected. Collectively these data indicate a differential modulation of villous versus extra villous trophoblast by 
hypoxia. 
In HUVEC cells, VEGF mRNA was shown also to be upre-gulated by hypoxia even though VEGF secretion in 
the conditioned medium cells was under the sensitivity threshold of the ELISA. In contrast, sVEGFR-1 in 
HUVEC cells was not modulated by hypoxia. Similar results were described earlier by Nagamatsu et al. (2004). 
As demonstrated by the ex vivo angiogenesis model of aorta ring assay, s VEGFR-1 counteracted angiogenesis 
induced by VEGF + PlGF. These results agree with the hypothesis that placental sVEGFR-1 secretion could 
contribute to maternal endothelial dysfunction. 
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sEng is an anti-angiogenic protein that inhibits TGF-β signaling in vasculature (Toporsian et al., 2005; 
Venkatesha et al., 2006). Endoglin is highly expressed on cell membranes of vascular endothelium and 
syncytiotrophoblasts (Cheifetz et al., 1992; Gougos et al., 1992). Recently, sEng has been implicated in the 
pathogenesis and prediction of pre-eclampsia, but high levels of sEng alone do not seem to be sufficient for the 
development of pre-eclampsia (Levine et al., 2006a). Recent data indicate that hypoxia activates the endoglin 
promoter and significantly induces endoglin gene expression in human microvascular endothelial cells (Li et al., 
2003). Our data are in agreement with those of Venkatescha et al. (2006) who suggested that sEng is probably 
the result of a proteolytic cleavage rather than the presence of an alternate splice variant in placenta. Our data 
indicate that the enhanced levels of sEng observed in pre-eclampsia are not directly linked to villous trophoblast 
exposure to hypoxia. 
In conclusion, our results support the hypothesis that, in preeclampsia, (i) overproduction of VEGF family 
factors by preeclamptic placenta is a consequence of induced hypoxia; (ii) overproduction of sVEGFR-1 by 
hypoxic villous trophoblast account for maternal free VEGF depletion; (iii) low circulating level of free PlGF is 
not only related to sVEGFR-1 overproduction, but also to hypoxia-induced mRNA down-regulation; (iv) sEng 
overproduction is probably due to an enhanced proteolytic cleavage independent of hypoxia. 
We have demonstrated the suitability of an in vitro first trimester villous expiant model for studying the effects 
of hypoxia in placental tissues and more interestingly, we demonstrated that the increase in sVEGFR-1 found in 
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